Small_Sphere.jpg
addiction-71538_640.jpg
Acetylcholine_receptor_Medium.jpg
E_ColiMulti.jpg
Virus_Cells_Large.jpg
Small_Sphere.jpg

Nano-based Drug Delivery


SCROLL DOWN

Nano-based Drug Delivery


Current approaches to modern drug delivery ultimately fail because of unwanted side affects.  These side effects include tissue accumulation, non-specific drug interactions or variable efficacy.  Our research interests currently focus on targeted drug delivery. With clinical advances including cellular targeting and new modalities for pharmaceutical delivery, it is anticipated that many of the harmful effects associated with existing drugs can be minimized.  Drug delivery platforms (DDP) assisted by nanotechnology are poised to redefine the space of modern pharmaceuticals.  Presently, innovations in drug delivery have fundamentally transformed the way in which new drugs are formulated.  Traditional drivers for pharmaceutical design - liberation, absorption, delivery, metabolism, and elimination (LADME)- have been expanded to include targeting, circulation time, triggered activation, and others.  As of 2012, it has been estimated that DDPs as a core technology are in 15% of the drug formulations coming online.  In fact, it has been posited that in the next 3-5 years, nano-enabled drug delivery may represent as much as 90% of the total market opportunity for novel drug design.  Peptineo was formed in 2011 to develop, market, and license patented drug discovery, drug delivery, and drug stabilization technologies.

 

addiction-71538_640.jpg

Marketplace Challenges


Challenges faced in the development of new drugs for Pharma

Marketplace Challenges


Challenges faced in the development of new drugs for Pharma

Problems Faced by Pharma

In today’s market for pharmaceuticals, drugs that follow traditional design principles continue to fail at the critical step of clinical trials due to toxicity. In many cases, this can be attributed to non-specific interactions in the body.  However, even if a drug does complete clinical trials, its indication for usage is often adjusted to limit risks associated with these same safety concerns and to minimize downstream implications for future liability. 

At present, the following represent key challenges that have an unmet need in the drug delivery industry:

  • Poor solubility
  • Systemic drug toxicity
  • Immune response
  • Drug accumulation and poor elimination
  • Poor circulation times and half-life
  • Patent protection
Acetylcholine_receptor_Medium.jpg

Discovery


Discovery


As a key initiative for our company, Peptineo is looking to bring a systems-based approach that includes computational modeling, pharmacology, protein engineering, and advanced drug carrier design to address unmet therapeutic challenges.  From basic research to clinical trials, we strive to identify for our clients innovative approaches to address ever evolving conditions seen in the clinical community.  Current activities include research into therapeutic peptides, reformulation of existing pharmacological compounds, and hybrid compounds that integrate modern, recombinant biological proteins with traditional chemical compounds. 

Additionally, Peptineo offers consulting services to clientele that require outsourced research and development of newly developed biological compounds. Current activities include consulting in the areas of biotechnology, pharmaceutical research, peptide synthesis and related development efforts.  We, also, as part of out consulting efforts, assist clients in areas of intellectual property to ensure that products developed as part of a contracted effort are protected for future use.

E_ColiMulti.jpg

Approach to Nanomedicine


Two minute animated movie explaining what nanomedicine is and applications for the technology.  Scroll down to view...

Approach to Nanomedicine


Two minute animated movie explaining what nanomedicine is and applications for the technology.  Scroll down to view...

An excellent overview of nanomedicine from the European Union (EU).  It describes perfectly technologies being developed by Peptineo .  Peptineo, a nanotechnology company based in Albuquerque, New Mexico, is currently developing commercial technologies around the use of novel polymeric materials for drug delivery applications.  In particular, one material under development, acetalated dextran (Ac-DEX), has recently been used as the basis for a novel vaccine under the direction of noted academic researchers and the US Department of Defense, Defense Advanced Research Projects Agency (DARPA).  Ac-DEX is also being reviewed for applications in which it could facilitate the re-introduction of failed late-stage drug candidates into the regulatory approval process.  In this case, it is anticipated that through its ability to precisely control the release of active pharmaceutical ingredients (APIs), Ac-DEX will offer a significantly better safety profile in numerous therapeutic applications.

Virus_Cells_Large.jpg

About Us


About Us


Who we are

With an expanding portfolio of intellectual property and interdisciplinary technical expertise, Peptineo represents the new face of biotechnology and bioengineering.  By employing a systems-based approach, Peptineo technical solutions involve drug delivery combinations including "tunable" nano-carriers, engineered peptides, re-formulated pharmaceuticals, and as appropriate, recombinant proteins.  To that end, Peptineo is developing solutions that reflect research efforts in computer science, systems biology, physics, molecular biology, pharmacology, protein engineering and biotechnology.  The employees of Peptineo believe that by having a broad range of technology and scientific expertise, Peptineo will have the resources required to efficiently address current or evolving clinical demands.